CTOs on the Move

JPT Peptide Technologies GmbH

www.jpt.com

 
JPT Peptide Technologies GmbH is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.jpt.com
  • PO BOX 2619
    Acton, MA USA 01720
  • Phone: 978.631.4225

Executives

Name Title Contact Details

Similar Companies

High Point Clinical Trials Center

High Point Clinical Trials Center is committed to the safe and ethical conduct of clinical trials for investigational drugs in a pleasant, comfortable environment for research participants. We recognize the importance of your decision to participate in a clinical trial and strive to guide you through the process with a knowledgeable and exciting experience. Your decision of being a research participant today may benefit generations to come. Our research trials and clinical studies include research on Alzheimer`s, diabetes, overweight and healthy individuals, and encompass individuals from the Greensboro, Winston-Salem, High Point areas of North Carolina, as well as throughout the US. We offer spacious comfortable living quarters, entertainment areas (media and games rooms), catered meals and wireless internet service for our participants. High Point Clinical Trials Center offers clinical studies and trials for Greensboro, Winston Salem, High Point residents, as well as throughout the US.

Oncology Plus

Oncology Plus is a Brandon, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TEI Biosciences

TEI Biosciences is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Yield10 Bioscience

Yield10 Bioscience is an agricultural bioscience company focusing on the development of disruptive technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. Experts forecast that food production must be increased by over 70% in the next 35 years to feed the growing global population, which is expected to increase from 7 billion to more than 9.6 billion by 2050. Yield10 is focused on new agricultural biotechnology approaches to improve fundamental elements of plant metabolism through enhanced photosynthetic efficiency and directed carbon utilization. Yield10 is working to develop, validate and commercialize new traits and identify gene editing targets in several key crops including canola, soybean and corn. Yield10 was launched by Metabolix, Inc. in 2015 and is traded on Nasdaq (YTEN). Yield10 is headquartered in Woburn, MA and has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.